Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 6/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25631758 | 0.99 | DDB1 (0.53) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL25631762 | 0.96 | DDB1 (0.51) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL25632146 | 0.91 | DDB1 (0.50) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL25631760 | 0.91 | DDB1 (0.50) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL22119507 | 0.89 | DDB1 (0.59) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL24480492 | 0.89 | GPR119 (0.66) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL25632150 | 0.88 | DDB1 (0.49) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL8346591 | 0.85 | GPR119 (0.53) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL27161752 | 0.85 | DDB1 (0.54) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL31134647 | 0.84 | DDB1 (0.59) | DDB1CRBNGPR119ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129074-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2025-04-24 | — | — | US | disclosed |
| EP-4438603-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-10-02 | — | — | EP | disclosed |
| US-20240269298-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2024-08-15 | — | — | US | disclosed |
| CN-118234726-A | Chimeric compound for androgen receptor protein targeted degradation, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4332100-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | Xizang Haisco Pharmaceutical Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| CN-117425646-A | Phosphono derivative, composition thereof and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-01-19 | — | — | CN | disclosed |
| WO-2023093845-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2023093845-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2023-06-01 | — | — | WO | disclosed |
| WO-2022228547-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240269298-A1 | PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | EGFR, BLK, CSNK1A1L | DDB1 3340/4885CRBN 2155/4885GPR119 1478/4885 |
| US-20250129074-A1 | CHIMERIC COMPOUND FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR PROTEIN, PREPARATION METHOD THEREFOR, AND MEDICAL USE THEREOF | AR, NR5A1, CYP17A1 | DDB1 4432/4885CRBN 743/4885GPR119 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.